Value-based care is conventionally classified as an alternative payment model. That classification mistakes the output for ...

In the early parallel years, hybrid rates ran 6.2 percentage points above digital-only rates in commercial plans and 9.3 ...

Six pending federal bills would regulate private equity in health care, from an outright ban to disclosure, licensing, and antitrust tools. Rather than a categorical ban, federal policy makers could ...

From regulatory efforts to streamline approvals to emerging AI-driven decision-making, this episode explores the forces ...

Our interest has not been to seek directly to narrow the compensation differentials that favor certain specialties over ...

The Evidence-Based Prevention Continuum provides a common language and understanding for how to categorize and scale such ...

This post examines the unique role of discrimination as a stressor and the part it plays in creating health inequities. Distinct from beliefs and stereotypes, discrimination refers to an action or ...

In their 2026 legislative sessions, state policymakers considered and enacted a wide variety of bills to improve affordability and strengthen their health care markets.

Medicare has created multiple opportunities to ask about fall risk. It has not created a dependable pathway to ensure that the answer changes care.

Rob Lott speaks with UC Berkeley's Niru Ghoshal-Datta about how changes to Medicare Advantage payments influenced plan offerings and enrollee costs.

Several strengths of the legacy commercial arbitration and litigation systems could inform improvements to the federal independent dispute resolution process established under the No Surprises Act.

One underrecognized contributor to the financial pressure on pharmacies is the outdated regulatory framework governing the return of expired or unused medications.